Direct-to-consumer marketing of osteoporosis drugs and bone densitometry

Annals of Pharmacotherapy

Volumn 37, Issue 7-8, 2003, Pages 976-981

  Hollon, Matthew F ^a,c   Larson, Eric B ^a   Koepsell, Thomas D ^b   Downer, Ann E ^b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c NONE   (United States)

Author keywords

Densitometry; Direct to consumer marketing; Healthcare utilization; Osteoporosis

Indexed keywords

ALENDRONIC ACID; ESTROGEN; LORATADINE; RALOXIFENE;

ADULT; ADVERTIZING; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONSUMER; CONTROLLED STUDY; DENSITOMETRY; DISEASE ASSOCIATION; DRUG MARKETING; EDUCATION; EVIDENCE BASED MEDICINE; FEMALE; HEALTH CARE UTILIZATION; HEALTH STATUS; HUMAN; MAMMOGRAPHY; OSTEOPOROSIS; PAPANICOLAOU TEST; PHARMACEUTICS; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; SCREENING TEST;

EID: 0037765186     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1C422     Document Type: Article

References (17)

1. Food and Drug Administration. Direct-to-consumer advertising of prescription drugs: withdrawal of moratorium. Federal Register 1985(September 9):36677-8.
2. IMS Health Incorporated. Prescription drug ad spending in U.S. exceeds $1.2 billion through November 1998. www.imshealth.com/html/news_arc/04_21_1999_192.htm (accessed 1999 April 22).
3. Holmer AF. Direct-to-consumer prescription drug advertising builds bridges between patients and physicians. JAMA 1999;281:380-2.
4. Hollon MF. Direct-to-consumer marketing of prescription drugs: creating consumer demand. JAMA 1999;281:382-4.
5. Hoffman JR, Wilkes M. Direct-to-consumer advertising of prescription drugs. An idea whose time should not come. BMJ 1999;318:1301-2.
6. Wilke M, Teinowitz I, Kelly KJ. Ad fever sweeps healthcare industry. Advertising Age 1997(January 13):1,18-9.
7. U.S. Preventive Services Task Force. Screening for postmenopausal osteoporosis. In: DiGuiseppi C, Atkins D, Woolf SH. eds. Guide to clinical preventive services. 2nd ed. Baltimore: Williams & Wilkins, 1996:509-16.
8. Sturtridge W, Lentle B, Hanley DA. Prevention and management of osteoporosis: consensus statements from the Scientific Advisory Board of the Osteoporosis Society of Canada. 2. The use of bone density measurement in the diagnosis and management of osteoporosis. CMAJ 1996;155:924-9.
9. Bone density measurement - a systematic review. A report from SBU, the Swedish Council on Technology Assessment in Health Care. J Intern Med 1997;739:1-60.
10. Genant HK. Interpretation of bone densitometry. Rev Rhum Engl Ed 1997;64(suppl 6):20S-5S.
11. Falasca GF, Alexandre C. Practical use of bone densitometry. Rev Rhum Engl Ed 1997;64(suppl 6):26S-30S.
12. Guidelines for the early detection of osteoporosis and prediction of fracture risk. Council of the National Osteoporosis Foundation. S Afr Med J 1996;86:1113-6.
13. The prevention and management of osteoporosis. Consensus statement. Australian National Consensus Conference 1996. Med J Aust 1997;167 (suppl):S1-15.
14. Selvin S. Statistical analysis of epidemiological data. 2nd ed. New York: Oxford University Press, 1996.
15. Hamm RM, Hicks RJ, Bemben DA. Antibiotics and respiratory infections: are patients more satisfied when expectations are met? J Fam Pract 1996;43:56-62.
16. Kravitz RL. Direct-to-consumer advertising of prescription drugs: implications for the patient-physician relationship. JAMA 2000;284:2244.
17. Bell RA, Kravitz RL, Thorn D, Krupat E, Azari R. Unmet expectations for care and the patient-physician relationship. J Gen Intern Med 2002;17:817-24.